Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares

6 days ago 4

Jonathan Ponciano, The Motley Fool

Mon, January 12, 2026 astatine 4:20 AM CST 5 min read

The president and CEO of Intellia Therapeutics sold 34,146 straight held shares of the steadfast connected Jan. 5.
The merchantability represented 3.09% of John M. Leonard’s nonstop holdings, arsenic reported.
All shares sold were from nonstop ownership; indirect holdings, including 58,415 shares successful the John M. Leonard 2015 Irrevocable Trust, were unaffected.
These 10 stocks could mint the adjacent question of millionaires ›

On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market merchantability of 34,146 straight held shares, totaling $314,484.66, arsenic disclosed successful a SEC Form 4 filing.

Metric

Value

Shares sold (direct)	34,146
Transaction value	$314,484.66
Post-transaction shares (direct)	1,013,339
Post-transaction shares (indirect)	58,415
Post-transaction worth (direct ownership)	$9,494,986

Transaction worth based connected SEC Form 4 reported terms ($9.21); post-transaction worth based connected the SEC-reported holding and the trade-date adjacent price.

How does the size of this transaction comparison to John M. Leonard’s anterior open-market sales?
This transaction progressive 34,146 shares, which is successful enactment with different income implicit the past, reinforcing a signifier of likewise sized dispositions.
What proportionality of Leonard’s nonstop and full Intellia holdings was affected by this sale?
The merchantability reduced his nonstop involvement to 1,013,339 shares post-transaction.
Was the merchantability executed from nonstop oregon indirect holdings, and are immoderate spot entities involved?
All shares sold originated from Leonard’s nonstop holdings; his indirect ownership, which includes 58,415 shares held by the John M. Leonard 2015 Irrevocable Trust, was unaffected.
Does the transaction bespeak a alteration successful selling cadence oregon capableness constraints?
The merchantability is successful enactment with the caller median for Leonard’s open-market activity, suggesting the cadence has not materially changed and that commercialized sizes person not been reduced owed to shrinking disposable stock capacity.

Metric

Value

Price (as of 1/5/26)	$9.21
Market capitalization	$1.09 billion
Revenue (TTM)	$57.53 million
Net income (TTM)	($445.81 million)

* 1-year show figures are calculated arsenic of Jan. 5.

Intellia Therapeutics develops successful vivo and ex vivo genome editing therapeutics targeting uncommon diseases, oncology, and autoimmune disorders; cardinal pipeline assets see NTLA-2001 (transthyretin amyloidosis), NTLA-2002 (hereditary angioedema), and NTLA-5001 (acute myeloid leukemia).
The institution operates a research-driven concern exemplary focused connected advancing proprietary CRISPR/Cas9-based therapies, generating gross chiefly done strategical collaborations and licensing agreements with pharmaceutical partners.
It serves biotechnology and pharmaceutical companies, arsenic good arsenic healthcare providers targeting patients with genetic, oncological, and autoimmune conditions.